Tenderwize
Zurück zur Suche

Pharmaceutical product with active ingredient Aripiprazole (ATC: N05AX12 - for parenteral administration)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 216 days left·Open·Supplies
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Aripiprazol (ATC: N05AX12 - für die parenterale Applikation)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

15 / 100

Risikofaktoren

The buyer may terminate contracts if exclusive contracts for the same active ingredient are later tendered during the c...

No estimated value or minimum volume is provided, making it impossible to assess potential revenue.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products with Aripiprazole (parenteral application) under an open-house model.
  • Any qualified pharmaceutical company can conclude a contract at any time under uniform conditions.
Vollständige Zusammenfassung anzeigen

This is a notice for non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for pharmaceutical products containing Aripiprazole (ATC: N05AX12, parenteral application) issued by AOK Sachsen-Anhalt. The procurement follows an 'open-house model' allowing any qualified pharmaceutical company to join at any time during the contract period (01.06.2025 to 31.05.2027). The tender is explicitly not a public procurement under EU law but published for transparency. No estimated value or award criteria are specified; all eligible companies get a contract without competition. The deadline for submission is 31.03.2027, with contracts starting as early as 01.06.2025.

Risiken

The buyer may terminate contracts if exclusive contracts for the same active ingredient are later tendered during the c...

No estimated value or minimum volume is provided, making it impossible to assess potential revenue.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or a group of pharmaceutical companies.

Administrative

  • Must complete and sign the participation documents.
  • Electronic submission allowed only via qualified electronic signature (eIDAS Regulation) to [email protected].

Anforderungen können unvollständig sein.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Pharmaceutical product with active ingredient Aripiprazole (ATC: N05AX12 - for parenteral administration)

Non-exclusive discount agreements for finished medicinal products with Aripiprazole (parenteral). The contract is open to all qualifying pharmaceutical companies at any time. No exclusivity; contracts end on 31.05.2027 regardless of start date. The buyer may terminate if exclusive contracts are later tendered.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Frist

Deadline Mar 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Apr 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
232943-2025

Dokumente (1)

Ähnliche Ausschreibungen